Stockreport

Annovis Bio Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntane...

Annovis Bio, Inc.  (ANVS) 
PDF Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo Changes in MDS-UPDRS a [Read more]